Compare RLX Technology Inc (RLX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs TransMedics Group Inc — how do they compare? RLX Technology Inc trades at $1.77 (market cap $2.19B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and RLX Technology Inc pays a 5.59% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| RLX | TMDX | |
|---|---|---|
Market Cap | $2.19B | $3.06B |
Sector | Technology | Technology |
52-Week High | $2.69 | $150.42 |
52-Week Low | $1.76 | $61.99 |
Enterprise Value | $919.18M | $3.46B |
Dividend Yield | 5.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX trades at $1.79, down 0.56% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue growth of 14.8% year-over-year, driven by international expansion, though it missed EPS estimates for the third consecutive quarter. Profitability remains solid with a net income margin of 21.87% and a P/E ratio of 16.1, indicating reasonable valuation.
The outlook is mixed; international growth offers opportunity, but consistent earnings misses and a sole 'Hold' analyst rating suggest caution. Key risks include execution in new markets and regulatory scrutiny. The stock lacks bullish momentum but holds fundamental strength if expansion delivers.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
